CD4 and tuberculosis: Accordingly, the Kaplan-Meier analysis indicated significant evidence of differences in survival times in the categories of past tuberculosis treatment, functional status, WHO clinical staging, baseline CD4 count, initial regimen types, substance abuse, disclosure status, and opportunistic infections (Table 3).